Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:2
Phase 3:1
Drug Approvals
78
FDA:75
NMPA:3
Drug Approvals
Moxifloxacin Hydrochloride Eye Drops
- Product Name
- 盐酸莫西沙星滴眼液
- Approval Number
- 国药准字HJ20180089
- Approval Date
- Jul 4, 2023
NMPA
Moxifloxacin Hydrochloride Eye Drops
- Product Name
- 盐酸莫西沙星滴眼液
- Approval Number
- 国药准字HJ20180088
- Approval Date
- Jul 4, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 3
1 (33.3%)No trials found
News
Alembic Pharmaceuticals Secures USFDA Approvals for Carbamazepine and Amlodipine-Atorvastatin Generics
Alembic Pharmaceuticals has received final USFDA approval for generic Carbamazepine 200 mg tablets, an anticonvulsant used for seizure disorders and neuropathic pain with a US market size of approximately $32 million.
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia
The FDA has granted accelerated approval to asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
GSK Acquires Boston Pharmaceuticals' Efimosfermin for Liver Disease in $2 Billion Deal
GSK has agreed to acquire Boston Pharmaceuticals' phase 3-ready liver disease candidate efimosfermin alfa for $1.2 billion upfront, with potential milestone payments bringing the total to $2 billion.